Anebulo Pharmaceuticals, Inc. ANEB

ANEB Company Overview

Anebulo Pharmaceuticals, Inc. is a U.S.-based clinical-stage biopharmaceutical company focused on developing treatments for acute cannabinoid intoxication and other substance-related disorders. The company operates within the biotechnology and pharmaceutical research and development industries, with no commercialized products as of the most recent publicly available filings. Its business model centers on advancing proprietary drug candidates through clinical development and, if successful, pursuing regulatory approval and commercialization.

The company’s primary asset is ANEB-001, an oral small-molecule candidate being evaluated for the treatment of acute cannabinoid intoxication. Anebulo’s strategic positioning is differentiated by its focus on an area with limited approved pharmacological treatments, targeting emergency department and acute care settings. Anebulo Pharmaceuticals was founded in 2020 and became publicly listed through an initial public offering in 2022, using the proceeds to fund clinical trials and general corporate operations.